Hypoxia-inducible factors, mTOR, and astrin constitute an integrative regulatory network in colon cancer cells

Abril Saint-Martin, Marco Antonio Morquecho-León, María Cristina Castañeda-Patlán, Martha Robles-Flores

Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad Universitaria, Cd, Mexico, 04510, Mexico

ARTICLE INFO

Keywords:
- Hypoxia-inducible factors
- mTOR regulation
- Astrin/SPAGS
- HIF-1α
- HIF-2α
- Colon cancer

ABSTRACT

Astrin/SPAGS is a mitotic spindle protein found to be overexpressed in several human cancers, functioning as an oncogene. The expression of Astrin has not been reported so far in colon cancer, nor has it been related to HIFs expression or action. Since mTOR, Astrin, and hypoxia-inducible factors (HIFs) are involved in promoting the growth and survival of cancer cells, we investigated the possible interaction between them in cultured colon cancer cells. Both Astrin and HIF-1α and HIF-2α protein levels were found only expressed in colon cancer cells compared with nonmalignant cells. Our data indicate that mTOR stimulates both Astrin and HIFs expression, but notably, mTORC activity seems to be independent of Astrin expression levels. However, while HIF-1α or HIF-2α stable knockdown increased Astrin expression, mTOR activity was affected in an opposite way by HIF-1α or HIF-2α silencing, indicating that HIF-1α inhibits mTOR while HIF-2α stimulates its activity. These data suggest that mTOR, Astrin, and HIFs compose an integrative network interacting to activate positive or negative regulatory loops probably to coordinate cancer cell growth, metabolism, and survival under oncogenic stress.

1. Introduction

The Ser/Thr kinase mTOR is a sensor of nutrients, growth factors, and stress signals, acting as a master regulator of growth, metabolism, autophagy, and cell survival in both nonmalignant and cancer cells [1]. Depending on its subunit composition, mTOR exists as two distinct complexes, mTORC1 and mTORC2, both including mTOR and sharing some components. The regulatory-associated protein of mTOR (Raptor) and the negative-regulator proline-rich Akt substrate 40 kDa (PRAS40) is only present in mTORC1. In contrast, the unique rapamycin-insensitive mTOR companion (Rictor) protein and the mammalian stress-activated MAPK interacting protein 1 (mSin1) are only present in mTORC2 [1,2].

The dysregulation of the PI3K/Akt or the Ras/ERK signaling pathways is widespread in many cancer types, including colon cancer, converging both pathways in mTOR activation. In nonmalignant cells, in the presence of nutrients and energy, mTOR induces anabolic processes but, in their absence, inhibits them and activates autophagy. Notably, mTOR inhibits Akt through negative feedback regulation, and thus its hyperactivation would ultimately provoke apoptosis cell death [1-3]. In cancer cells, mTOR becomes activated due to the altered oncogenic signaling pathways and oxidative stress [1]. Cancer cells have evolved protective tools to avoid the mTOR hyperactivation-induced cell death while maintaining mTORC activity and the survival mechanisms it induces. Among them are metabolic reprogramming, induction of antioxidant protein synthesis, and induction of stress granule formation [4]. The Sperm-associated Antigen 5 (SPAG5), or Astrin, is a mitotic spindle protein overexpressed in several human cancers that functions as an oncogene [5,6]. It has been reported that Astrin competes with mTOR for Raptor binding and recruits mTOR to stress granules, suggesting that in this way, Astrin may prevent mTORC1 hyperactivation-induced apoptosis [7]. Stress granules then would function as sentinels of mTORC1 signaling, allowing cancer cells to escape stress-induced cell death [4,7].

In addition to oncogenic mTORC signaling, hypoxia resulting in nutrient depletion is a hallmark of the tumoral microenvironment. The hypoxia-inducible factors (HIFs) regulate the cellular adaptation to oxygen deprivation and play key roles in cancer biology [8,9]. Remarkably, in cancer cells, HIFs upregulation often occurs without hypoxic conditions because its expression can be induced by oncogenic signaling by several mechanisms [10]. The expression of Astrin has not been reported so far in colon cancer, nor has it been related to HIFs expression.
or action. In this work, we found that colon cancer cells overexpress Astrin. Our data indicate that mTORC controls both Astrin and HIFs expression, but its activity seems to be independent of Astrin expression levels. However, mTORC activity is affected in an opposite way by HIF-1α or HIF-2α. Our data suggest that mTORC, Astrin, and HIFs constitute an integrative regulatory network in colon cancer cells.

2. Materials and methods

Reagents and antibodies. Hydroxychloroquine and Temsirolimus (CCI-779) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The antibodies used in the experiments were obtained from the following sources: anti-Astrin/SPAG5 was obtained from Santa Cruz Biotechnology Inc (Sta. Cruz, CA, USA); anti-HIF-1α, anti-HIF-2α, anti-β-tubulin, and anti-Phospho-S6 Ribosomal protein (Ser235/236) were obtained from Cell Signaling Technology (Danvers, MA, USA). Goat anti-mouse and anti-rabbit IgG-horseradish peroxidase-conjugates were obtained from Pierce (Rockford, IL, USA).

Plasmids. The control plasmid containing a scrambled shRNA sequence was obtained from Santa Cruz Biotechnology. The control plasmid (void pSuper), HIF-1α, and HIF-2α RNAi plasmids were donated by Dr. Daniel Chung, and their construction and effectiveness were previously described [11–13].

Cell lines and treatments. All colon cancer cell lines (RKO, SW480, and SW620) and the nonmalignant 112CoN cell line used were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) and were authenticated by Short Tandem Repeat DNA profiling in June 2017 at the Instituto Nacional de Medicina Genómica (INMEGEN) in Mexico City. All cells were cultured in a humidified 5% CO2 incubator at 37 °C. The human RKO and primary SW480 cell lines used in our study have oncogenic driver mutations that result in mTORC1 activation [14,15]. Our data suggest that mTORC, Astrin, and HIFs constitute an integrative regulatory network in colon cancer cells.

3. Results and discussion

The mitotic spindle protein Astrin/SPAG5, overexpressed in malignant cells, has been implicated in neoplastic growth, chemoresistance, metastasis, and overall survival of several cancer types [5,6]. HIFs over-expression has been previously reported in many cancer types under normoxic conditions [9], and we have also previously reported this in colon cancer cells [15,17]. To investigate if Astrin is expressed in colon cancer cells, we analyzed its protein levels by Western blotting in several cultured colon cancer cells compared with the levels found in colon nonmalignant cells. Fig. 1 panel A shows that Astrin is expressed as two isoforms only in colon malignant cells (RKO, SW480, and SW620) but not in nonmalignant 112-CoN cells. We also confirmed that both HIF-1α and HIF-2α are also only expressed in colon malignant cells under normoxic conditions (Fig. 1 panel B).

Hyoxia and subsequent nutrient depletion, along with a hyperactive metabolism, and oncogenic mTOR signaling, are conditions frequently found in tumors [18]. mTOR coordinates cell growth and metabolism by integrating growth factor signaling with survival signaling in cancer cells, thus functioning as a nutrient and as a stress sensor [1,18]. To investigate the effect of mTORC1 inhibition on HIF-1α or HIF-2α expression, SW480 cells were incubated for 48 h in the presence of 10 μM of CCI-779 (Temsirolimus). The inhibition of mTORC1 was determined by incubating cells with the rapamycin analog CCI-779 (Temsirolimus). HIFs-induced autophagy may be abolished to increase the cytotoxicity of mTOR inhibition through hydroxychloroquine (HCQ), which prevents the fusion of autophagosomes with lysosomes, the final step of autophagy [15,16]. The doses used for the experiments performed were the following: 20 μM of HCQ, which had no inhibitory effect on cell viability and was reported as a dose necessary to inhibit autophagy without affecting cell viability [15], and 20 μM of CCI-779 to inhibit phosphorylation of p70 ribosomal S6 Kinase, a typical substrate of mTORC1 [15,16].
Fig. 2. Inhibition of mTORC with CCI-779 diminishes both HIF-1α and HIF-2α expression levels. SW480 cells were treated with 20 μM CCI-779 for 48 h. A) HIF-1α, HIF-2α and Phospho-S6K expression levels were analyzed in cell extracts by Western blotting. β-tubulin was used as a control for equal loading. B) Densitometric analysis was performed to estimate the changes in PhosphoS6K and HIFs expression levels with respect to β-tubulin expression. The data are presented as the mean values ± SEM from at least three independent experiments, **p < 0.05, ***p < 0.005.

Fig. 3. Knockdown of HIF-1α or HIF-2α increased Astrin expression but the effect of each HIF knockdown on mTORC activity was opposed. A) The efficiency of HIF-1α or HIF-2α knockdown was evaluated in SW480 cells by Western blot. Tubulin was used as a control for equal loading. B–C) Control or HIF-1α (panel B) or HIF-2α (panel C) -silenced SW480 cells were incubated with 20 μM CCI-779 alone, with 20 μM HCQ, or in combination with both agents for 48 h. Astrin expression levels were analyzed in cell extracts by Western blotting. Densitometric analysis was performed in each panel to estimate the Astrin expression with respect to the control β-tubulin expression levels. The data are presented as the mean values ± SEM from at least three independent experiments. **p < 0.01, ***p < 0.001.
absence or presence of the mTORC1 inhibitor Temsirolimus (CCI-779). The efficiency of mTOR inhibition was demonstrated by the negative effect obtained in the phosphorylation status of the typical mTORC substrate, the p70 ribosomal S6 protein Kinase (p70-S6K, at Thr389), as can be observed in Fig. 2. Consistent with previous reports suggesting that the expression of both HIF-1α and HIF-2α is dependent on mTOR [18–20], the results shown in this figure also indicate that the expression levels of both HIF-1α and HIF-2α obtained by Western blotting and densitometric analysis were significantly diminished by mTORC inhibition.

To block the expression of HIFs, stable transfected SW480 cells with the control scrambled shRNA plasmid, with HIF-1α RNAi, or with HIF-2α RNAi were selected with 3 μg/mL puromycin (Sigma) or 5 μg/mL G418 (Sigma), respectively, during four weeks. The clones were selected, and the silencing efficiency was examined by Western blotting, as shown in Fig. 3A. The stable knockdown of either HIF-1α (Fig. 3 panel B) or HIF-2α (Fig. 3 panel C) in colon cancer cells induced a significant increase in both Astrin isoforms expression levels. In addition, in both panels B and C of Fig. 3, it can also be observed that the inhibition of mTORC1 with the rapamycin analog CCI-779 diminished Astrin expression, alone or in combination with the autophagy flux inhibitor Hydroxychloroquine (HCQ), which alone did not produce any significant effect. Thus, combining the results obtained in Figs. 2 and 3 data indicate that mTORC inhibition negatively affects both Astrin and HIFs expression.

However, when we investigated the effect of HIFs knockdown on mTORC activity, remarkably, it was found that the effect of each HIF knockdown on mTORC activity was opposed: knockdown of HIF-1α (Fig. 4 panel A) resulted in mTORC activity enhancement, visualized as an increase in the phosphorylation of its typical substrate, p70-S6K (P–S6K). Conversely, HIF-2α silencing (Fig. 4 panel B) resulted in mTORC activity inhibition, visualized as a decrease in p70-S6K phosphorylation. Treatment of cells with the combination of CCI-779 and the autophagy flux inhibitor Hydroxychloroquine (HCQ) did not produce significant effects compared with CCI-779 treatment alone, except when cells were depleted of HIF-2α expression. These results agree with those reported by Elorza A et al. [21], which found that activation of the HIF2α pathway in VHL-deficient tumor cells derived from renal cell carcinoma increases mTORC1 activity by upregulating the expression of SLC7A5, an amino acid carrier critical for its activity.

Cancer cells require mTORC1 activity, but mTORC1 hyperactivation would sensitize cells to death by apoptosis [1–3]. Stress granules (SGs) represent important non-membrane cytoplasmic compartments involved in cellular adaptation to stressful conditions such as hypoxia, nutrient deprivation, and oxidative stress allowing cancer cells to escape stress-induced cell death [4]. Notably, Thedieck et al. [7] described Astrin as an essential negative mTORC1 regulator because they showed that Astrin interacts with Raptor recruiting it to SGs to restrict mTORC1 activation upon stress, proposing that mTOR-Raptor dissociation may be a compensatory mechanism to prevent mTORC1 hyperactivation and apoptosis upon stress [7]. However, our results are not consistent with the notion of Astrin as a negative modulator of mTOR activity. Notably, our data indicate that mTORC activity seems to be independent of Astrin expression levels because, as shown in Fig. 3A, HIF-1α expression knockdown greatly increased Astrin expression levels, and despite this,
mTORC activity did not result diminished but on the contrary, displayed high activity when HIF-1α expression was depleted as shown in Fig. 4A. Our data are instead in agreement with recent reports showing that Astrin plays a key role in activating many signaling pathways that are known to be associated with cancer, such as the PI3K/AKT/mTOR signaling pathway [6,22–24].

Altogether our data indicate that it is mTORC that controls both HIFs and Astrin expression connecting them in a survival regulatory mechanism under stress conditions. However, this does not rule out that both Astrin and HIF-1α expression may be part of negative feedback loop regulations to avoid mTORC hyperactivation and apoptosis induction in colon cancer cells. In addition, mTORC also activates a positive loop mechanism under stress conditions. However, this does not rule out that both and Astrin expression connecting them in a survival regulatory mechanism [6, 22].

Our data are instead in agreement with recent reports showing that HIFs, and Astrin may adjust the cellular response to them.

Ethics statements

This work does not include any human subjects, animal experiments, or data from social media platforms.

CRediT author statement

Añedro Saint-Martin: Conceptualization, Methodology, Data curation, Formal analysis. Marco Antonio Morquecho-León: Methodology, Formal analysis. María Cristina Castañeda-Patlán: data curation, validation, supervision. Martha Robles-Flores: Conceptualization, validation, formal analysis, investigation, Resources, Writing-Review & Editing, Funding acquisition.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

Marco Antonio Morquecho-León was granted with a Postdoctoral Fellowship by DGAPA, Universidad Nacional Autónoma de México (UNAM), and Abril Saint-Martin was granted with a Postdoctoral Fellowship by CONACYT, Mexico.

This research was supported by grants from Universidad Nacional Autónoma de México (DGAPA/UNAM IN215514 and IN225717) and by Conacyt (FOSSIS 2017–289600).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbrep.2022.101336.

References

[1] A.M. Heberle, M.T. Pretzell, K. van Eunen, B.M. Bakker, S.N. Grellscheid, K. Theiediek, Molecular mechanisms of mTOR regulation by stress, Mol. Cell. Oncol. 2 (2) (2015), e970489.

[2] D. Meng, A.R. Frank, J.L. Jewell, mTOR signaling in stem and progenitor cells, Development 145 (2018) dev152595, https://doi.org/10.1242/dev.152595.

[3] N.P. Shakhare, K. Bray, R.T. Abraham, The PI3K, metabolic and autophagy networks: interactive partners in cellular health and disease, Annu. Rev. Pharmacol. Toxicol. 53 (2013) 89–106.

[4] N. Legrand, D.A. Dixon, C. Sobolewski, Stress granules in colorectal cancer: current knowledge and potential therapeutic applications, World J. Gastroenterol. 26 (35) (2020) 5223–5247.

[5] J. He, A.R. Green, Y. Li, S.Y.T. Chan, D.-X. Liu, Spag5: an emerging oncogene, Trends in Cancer 6 (2020) 543–547.

[6] Z. Ying, J. Yang, W. Li, X. Wang, Z. Zhu, W. Jiang, Ch Li, O. Sha, Astrin: a key player in mitosis and cancer, Front. Cell Dev. Biol. 8 (2020) 866.

[7] K. Theiediek, B. Holzwarth, M.T. Pretzell, C. Boehlke, K. Kläsener, S. Ruf, A. G. Sonntag, L. Maerz, S.-N. Grellscheid, E. Kremmer, R. Nitschke, E.W. Kuehn, J. W. Jonker, A.K. Groen, M. Ret, M.N. Hall, R. Baumeister, Inhibition of mTORC1 by Astrin and stress granules prevents apoptosis in cancer cells, Cell 154 (2013) 859–874.

[8] G.L. Semenza, Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy, Trends Pharmacol. Sci. 33 (2012) 207–214.

[9] A. Saint-Martin, M.C. Castañeda-Patllán, M. Robles-Flores, The role of hypoxia inducible factors in cancer resistance, J Cell Signal 2 (2017) 154, https://doi.org/10.4172/2161-0495.1000154.

[10] A. Elorza, I. Soro-Arneda-Patlán, E. García-Zepeda, M. Robles-Flores, Functional interaction of hypoxia inducible factor-1 alpha and 2 alpha on mTORC1 and mTORC2, J. Biol. Chem. 283 (2008) 34495–34499.

[11] T. Iinuma, H. Ikuchik, M.T. Herrait, D.Y. Park, Y. Mizukami, M. Mino-Kendus, M.P. Lynch, B.R. Rueda, Y. Benita, R.J. Xavier, D.C. Chung, HIF-1 and HIF-2 have divergent roles in colon cancer, Int. J. Cancer 124 (2009) 763–771.

[12] Y. Mizukami, J. Li, X. Zhang, M.A. Zimmer, O. Biopolouco, D.C. Chung, Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer, Cancer Res. 64 (2004) 1765–1772.

[13] O. Aprelikova, G.V. Chandramouli, M. Wood, J.R. Vasselli, J. Riss, J.K. Maranich, W.M. Linehan, J.C. Barrett, Regulation of HIF prolylhydroxylases by hypoxia-inducible factors, J. Cell. Biochem. 92 (2004) 491–501.

[14] D. Ahmed, P.W. Eide, L.A. Eilersen, S.A. Danielson, M. Eknas, M. Hektoen, et al., Epigenetic and genetic features of 24 colon cancer cell lines, Oncogenesis 2 (2013) e71, https://doi.org/10.1038/ oncgene.2013.

[15] A. Saint-Martin, J. Martínez-Ríos, M.C. Castañeda-Patlán, A. Barribia-Sánchez, N. Tejeda-Muñoz, A. Chinney-Herrera, G. Soldevila, R. Bellenni, P. Santoyo-Ramos, A. Poggi, M. Robles-Flores, Functional interaction of hypoxia inducible factor 2-alpha and autophagy mediates drug resistance in colon cancer cells, Cancers 11 (2019) E755, https://doi.org/10.3390/cancers11060755, PI.

[16] A. Xie, E.P. White, J.M. Mehnert, Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma, PLoS One 8 (2013), e55096.

[17] P. Santoyo Ramos, M. Likhatcheva, M.C. Castañeda-Patllán, E. García-Zepeda, M. Robles-Flores, Hypoxia-inducible factors participate in the modulation of stemness and malignancy of colon cancer cells playing opposite roles in canonical Wnt signaling, PLoS One 9 (2014), e125880.

[18] Y. Chun, J. Kim, AMPK-mTOR signaling and cellular adaptations in hypoxia, Int. J. Mol. Sci. 22 (2021) 9765, https://doi.org/10.3390/ijms22189765.

[19] A. Toschi, E. Lee, N. Gad, M. Ohh, D.A. Foster, Differential dependence of hypoxia inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2, J. Biol. Chem. 283 (2008) 34495–34499.

[20] S. Mohlin, A. Hamidian, R.T. Abraham, The PI3K, metabolic and autophagy networks: interactive partners in cellular health and disease, Annu. Rev. Pharmacol. Toxicol. 53 (2013) 89–106.

[21] A. Elorza, I. Soro-Arneda-Patlán, E. Meléndez-Rodríguez, V. Rodríguez-Vaello, G. Marsboom, G. de Cárden, B. Acosta-Borrallo, et al., HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5, Mol. Cell. 48 (2012) 681–691.

[22] G. Liu, S. Liu, G. Cao, W. Luo, P. Li, S. Wang, Y. Chen, SPAG5 contributes to the progression of gastric cancer by upregulation of Survivin depend on activating the Wnt/β-catenin pathway, Exp. Cell Res. 379 (2019) 81–91.

[23] Y.-F. Yang, M.-F. Zhang, Q.-H. Tian, J. Fu, X. Yang, C.Z. Zhang, et al., SPAG5 interacts with CEPP5 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma, Mol. Cell. 17 (2018) 117, https://doi.org/10.1186/s12943-018-0872-3.

[24] J. Jiang, J. Wang, X. He, W. Ma, L. Sun, Q. Zhou, et al., High expression of SPAG5 sustains the malignant growth and invasion of breast cancer cells through the activation of Wnt/β-catenin signaling, Clin. Exp. Pharmacol. Physiol. 46 (2019) 597–606, https://doi.org/10.1111/1440-1681.13082.